Everstring

EverString’s AI SaaS solution is designed for B2B sales and marketing professionals to drive pipeline growth, help close new customers, expand into new markets, prioritize accounts, and provide actionable insights – all without the need for an administrator. EverString is backed by leading investors including Lightspeed Venture Partners, Sequoia Capital, IDG Ventures and Lakestar.

C-Suite On Deck

Matt Amundson, VP of Marketing at EverString has over 10 years of sales and marketing experience. Matt has held roles in Demand Generation and Sales Development at TIBCO, Marketo, FGXI and Red Bull. His primary focus has been on creating processes that generate a consistent, pipeli...

Events

Related News

MEDTECH

FLAMINGO THERAPEUTICS EXPANDS ALLIANCE WITH IONIS PHARMACEUTICALS TO DEVELOP RNA-TARGETED THERAPIES FOR ONCOLOGY

Flamingo Therapeutics, Inc. | September 09, 2021

news image

Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer. This alliance is an expansion of an existing collaboration with Ionis on the FLAME™ discovery engine, following Flamingo's Series A financing in 2020. The agreement and discovery alliance will leverage Flamingo's de...

Read More

CELL AND GENE THERAPY

ELASTRIN THERAPEUTICS ANNOUNCES NEWLY FORMED SCIENTIFIC ADVISORY BOARD

Elastrin Therapeutics Inc. | January 17, 2022

news image

Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board. The Board is comprised of leading industry and university experts in cardiovascular research and clinical development. Former CMO of Elastrin Therapeutics, Dr. Pedro M. Quintana Diez, will act as chairman. Elastrin Therapeutics’ lead asset ELT-001 is an EDTA...

Read More

BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCED THE LAUNCH OF THE COVID-SEROINDEX, A KANTARO QUANTITATIVE SARS-COV-2 IGG ANTIBODY RUO KIT

Bio-Techne | August 04, 2020

news image

Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available ...

Read More

MEDICAL

BIOAGILYTIX TO PURCHASE AUSTRALIA-BASED 360BIOLABS®

BioAgilytix | August 17, 2021

news image

BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds ...

Read More
news image

MEDTECH

FLAMINGO THERAPEUTICS EXPANDS ALLIANCE WITH IONIS PHARMACEUTICALS TO DEVELOP RNA-TARGETED THERAPIES FOR ONCOLOGY

Flamingo Therapeutics, Inc. | September 09, 2021

Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer. This alliance is an expansion of an existing collaboration with Ionis on the FLAME™ discovery engine, following Flamingo's Series A financing in 2020. The agreement and discovery alliance will leverage Flamingo's de...

Read More
news image

CELL AND GENE THERAPY

ELASTRIN THERAPEUTICS ANNOUNCES NEWLY FORMED SCIENTIFIC ADVISORY BOARD

Elastrin Therapeutics Inc. | January 17, 2022

Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board. The Board is comprised of leading industry and university experts in cardiovascular research and clinical development. Former CMO of Elastrin Therapeutics, Dr. Pedro M. Quintana Diez, will act as chairman. Elastrin Therapeutics’ lead asset ELT-001 is an EDTA...

Read More
news image

BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCED THE LAUNCH OF THE COVID-SEROINDEX, A KANTARO QUANTITATIVE SARS-COV-2 IGG ANTIBODY RUO KIT

Bio-Techne | August 04, 2020

Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available ...

Read More
news image

MEDICAL

BIOAGILYTIX TO PURCHASE AUSTRALIA-BASED 360BIOLABS®

BioAgilytix | August 17, 2021

BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds ...

Read More

Resources

Events

C-Suite On Deck

Matt Amundson, VP of Marketing at EverString has over 10 years of sales and marketing experience. Matt has held roles in Demand Generation and Sales Development at TIBCO, Marketo, FGXI and Red Bull. His primary focus has been on creating processes that generate a consistent, pipeli...